Health · 1 sources covering this

STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more

The FDA said a Capricor stem cell treatment for Duchenne muscular dystrophy did not meet a Phase 3 trial's objectives — contrary to company claims

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more
The FDA said a Capricor stem cell treatment for Duchenne muscular dystrophy did not meet a Phase 3 trial's objectives — contrary to company claims
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/b2e698bcbfb4b31c3208a5c906bff71b844d99b5"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Pharmalittle: We&#8217;re reading about FDA views on a Duchenne drug, GSK cost savings, and more"></iframe>

STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more

How 1 sources are covering this

STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more

More from Health

STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment

STAT+: Three questions with Whoop’s new CMO

Anthony Fauci’s pandemic-era diary entries

STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Pharmalittle: We&#8217;re reading about FDA views on a Duchenne drug, GSK cost savings, and more

More from Health

STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment

STAT+: Three questions with Whoop&#8217;s new CMO

Anthony Fauci’s pandemic-era diary entries

STAT+: Preliminary trial results suggest a path to a safer Alzheimer&#8217;s treatment

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more

STAT+: Three questions with Whoop’s new CMO

STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment